Mirage News·3 min read·medium
KRAS Vaccine Spurs Immune Response in High-Risk Patients
✦AI Summary
Researchers at Johns Hopkins have successfully tested an experimental vaccine targeting KRAS mutations in high-risk pancreatic cancer patients. The phase 1 trial showed that 90% of participants developed a durable immune response, marking a potential breakthrough in cancer prevention.
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in